Glenmede Trust Co. NA cut its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 8.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,639,173 shares of the biopharmaceutical company’s stock after selling 317,808 shares during the quarter. Glenmede Trust Co. NA owned approximately 2.22% of Horizon Pharma worth $53,130,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the stock. Advantage Investment Management LLC raised its position in shares of Horizon Pharma by 164.8% during the third quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 4,900 shares during the last quarter. Brown Advisory Inc. bought a new stake in Horizon Pharma in the third quarter worth approximately $145,000. BlueCrest Capital Management Ltd bought a new stake in Horizon Pharma in the fourth quarter worth approximately $160,000. K2 Principal Fund L.P. increased its holdings in Horizon Pharma by 126.1% in the fourth quarter. K2 Principal Fund L.P. now owns 11,074 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 53,574 shares in the last quarter. Finally, Zeke Capital Advisors LLC bought a new stake in Horizon Pharma in the fourth quarter worth approximately $167,000. 86.75% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have recently commented on the company. Cantor Fitzgerald set a $17.00 price objective on Horizon Pharma and gave the company a “buy” rating in a report on Monday, January 8th. BidaskClub raised Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, March 28th. UBS set a $20.00 price objective on Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, March 1st. Finally, ValuEngine cut Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $18.64.
HZNP stock traded down $0.54 during trading on Friday, hitting $13.65. 2,132,700 shares of the company traded hands, compared to its average volume of 1,656,638. Horizon Pharma PLC has a 1 year low of $9.45 and a 1 year high of $16.02. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.63 and a quick ratio of 1.54. The stock has a market capitalization of $2,251.92, a PE ratio of 11.57, a P/E/G ratio of 0.58 and a beta of 1.24.
Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.07. The firm had revenue of $274.22 million during the quarter, compared to analyst estimates of $264.48 million. Horizon Pharma had a positive return on equity of 18.44% and a negative net margin of 38.87%. The business’s revenue was down 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 EPS. analysts anticipate that Horizon Pharma PLC will post 1.43 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Glenmede Trust Co. NA Trims Stake in Horizon Pharma PLC (NASDAQ:HZNP)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/horizon-pharma-plc-hznp-position-cut-by-glenmede-trust-co-na.html.
Horizon Pharma Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.